ECSP088939A - Carboxamidas sustituidas como antagonistas del receptor metabotropico del grupo i - Google Patents

Carboxamidas sustituidas como antagonistas del receptor metabotropico del grupo i

Info

Publication number
ECSP088939A
ECSP088939A EC2008008939A ECSP088939A ECSP088939A EC SP088939 A ECSP088939 A EC SP088939A EC 2008008939 A EC2008008939 A EC 2008008939A EC SP088939 A ECSP088939 A EC SP088939A EC SP088939 A ECSP088939 A EC SP088939A
Authority
EC
Ecuador
Prior art keywords
carboxamids
metabotropic
antagonists
receiver
replaced
Prior art date
Application number
EC2008008939A
Other languages
English (en)
Spanish (es)
Inventor
Kumiko Takeuchi
Edward C R Smith
Matthew Joseph Fisher
Ryan Thomas Backer
Steven Lee Kuklish
Sean Patrick Hollinshead
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP088939A publication Critical patent/ECSP088939A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EC2008008939A 2006-06-08 2008-12-03 Carboxamidas sustituidas como antagonistas del receptor metabotropico del grupo i ECSP088939A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81183906P 2006-06-08 2006-06-08

Publications (1)

Publication Number Publication Date
ECSP088939A true ECSP088939A (es) 2009-01-30

Family

ID=39673278

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008939A ECSP088939A (es) 2006-06-08 2008-12-03 Carboxamidas sustituidas como antagonistas del receptor metabotropico del grupo i

Country Status (30)

Country Link
US (1) US7960419B2 (https=)
EP (1) EP2076502B1 (https=)
JP (1) JP5108878B2 (https=)
KR (1) KR101051559B1 (https=)
CN (1) CN101466691B (https=)
AT (1) ATE509921T1 (https=)
AU (1) AU2007347428B2 (https=)
BR (1) BRPI0712862A2 (https=)
CA (1) CA2652074C (https=)
CR (1) CR10410A (https=)
CY (1) CY1111588T1 (https=)
DK (1) DK2076502T3 (https=)
EA (1) EA014233B1 (https=)
EC (1) ECSP088939A (https=)
ES (1) ES2362949T3 (https=)
HR (1) HRP20110436T1 (https=)
IL (1) IL195632A (https=)
MA (1) MA30620B1 (https=)
MX (1) MX2008015485A (https=)
MY (1) MY148084A (https=)
NO (1) NO341474B1 (https=)
NZ (1) NZ573352A (https=)
PL (1) PL2076502T3 (https=)
PT (1) PT2076502E (https=)
RS (1) RS51818B (https=)
SI (1) SI2076502T1 (https=)
TN (1) TNSN08506A1 (https=)
UA (1) UA95480C2 (https=)
WO (1) WO2008103185A2 (https=)
ZA (1) ZA200809111B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0804685D0 (en) 2008-03-13 2008-04-16 Univ Edinburgh Therapeutic compounds and their use
CA2720631C (en) 2008-04-04 2012-08-28 Eli Lilly And Company 3-indazolyl-4-pyridylisothiazoles
EP2443113A1 (en) * 2009-06-15 2012-04-25 The University Of Edinburgh Amido-isothiazole compounds and their use as inhibitors of 11beta-hsd1 for the treatment of metabolic syndrome and related disorders
EP2477983B1 (en) 2009-09-16 2015-04-15 The University Of Edinburgh (4-phenyl-piperidin-1-yl)-[5-1h-pyrazol-4yl)-thiophen-3-yl]-methanone compounds and their use
WO2011135276A1 (en) 2010-04-29 2011-11-03 The University Of Edinburgh 3, 3 -disubstituted- ( 8 - aza - bicyclo [3.2.1] oct- 8 - yl) -[5- (1h - pyrazol - 4 -yl) -thiophen-3 -yl] methanones as inhibitors of 11 (beta) -hsd1
ES2641469T3 (es) 2012-11-13 2017-11-10 Nissan Chemical Industries, Ltd. Compuesto de 2-piridona
WO2018054846A1 (de) 2016-09-23 2018-03-29 Bayer Aktiengesellschaft N3-cyclisch substituierte thienouracile und ihre verwendung
CN117567266B (zh) * 2023-11-07 2024-06-14 康龙化成手性医药技术(宁波)有限公司 一种制备2-甲基环丙羧酸的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL72091A0 (en) * 1983-06-20 1984-10-31 Lilly Co Eli N'-substituted(3-aryl 5-isothiazolyl)urea derivatives
DE4328425A1 (de) * 1993-08-24 1995-03-02 Basf Ag Acylamino-substituierte Isoxazol- bzw. Isothiazolderivate, Verfahren zu deren Herstellung und ihre Verwendung
DK124393D0 (da) * 1993-11-03 1993-11-03 Lundbeck & Co As H Compounds
DE19542372A1 (de) * 1995-11-14 1997-05-15 Bayer Ag Acylierte 5-Aminoisothiazole
UA60365C2 (uk) * 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
JP3411262B2 (ja) * 1999-08-20 2003-05-26 萬有製薬株式会社 新規スピロ化合物
EP1435948A1 (en) * 2001-08-06 2004-07-14 Pharmacia Italia S.p.A. Aminoisoxazole derivatives active as kinase inhibitors
WO2005030128A2 (en) * 2003-09-23 2005-04-07 Merck & Co., Inc. Pyrazole modulators of metabotropic glutamate receptors
WO2005113534A2 (en) * 2004-05-12 2005-12-01 Schering Corporation Cxcr1 and cxcr2 chemokine antagonists
JP2008513434A (ja) * 2004-09-23 2008-05-01 ファイザー・プロダクツ・インク トロンボポイエチン受容体アゴニスト

Also Published As

Publication number Publication date
UA95480C2 (uk) 2011-08-10
SI2076502T1 (sl) 2011-09-30
CA2652074C (en) 2013-08-06
EP2076502B1 (en) 2011-05-18
IL195632A (en) 2013-11-28
IL195632A0 (en) 2009-09-01
NO341474B1 (no) 2017-11-27
JP2009539874A (ja) 2009-11-19
KR20090008460A (ko) 2009-01-21
MX2008015485A (es) 2009-03-06
CA2652074A1 (en) 2008-08-28
CN101466691B (zh) 2011-07-27
WO2008103185A2 (en) 2008-08-28
PT2076502E (pt) 2011-06-07
MY148084A (en) 2013-02-28
HK1131984A1 (en) 2010-02-12
BRPI0712862A2 (pt) 2012-12-18
PL2076502T3 (pl) 2011-09-30
ZA200809111B (en) 2009-12-30
TNSN08506A1 (en) 2010-04-14
HRP20110436T1 (hr) 2011-08-31
NO20085028L (no) 2008-12-02
MA30620B1 (fr) 2009-08-03
US7960419B2 (en) 2011-06-14
CN101466691A (zh) 2009-06-24
EP2076502A2 (en) 2009-07-08
RS51818B (sr) 2011-12-31
EA200870516A1 (ru) 2009-06-30
NZ573352A (en) 2011-10-28
DK2076502T3 (da) 2011-07-25
JP5108878B2 (ja) 2012-12-26
AU2007347428A1 (en) 2008-08-28
CR10410A (es) 2008-11-28
ES2362949T3 (es) 2011-07-15
KR101051559B1 (ko) 2011-07-22
CY1111588T1 (el) 2015-10-07
AU2007347428B2 (en) 2012-02-09
US20090182025A1 (en) 2009-07-16
ATE509921T1 (de) 2011-06-15
WO2008103185A3 (en) 2008-10-30
EA014233B1 (ru) 2010-10-29

Similar Documents

Publication Publication Date Title
EA201690033A2 (ru) Морфинановые соединения
ECSP088939A (es) Carboxamidas sustituidas como antagonistas del receptor metabotropico del grupo i
GEP20115140B (en) Substituted spirocyclic cgrp receptor antagonists
IL184932A0 (en) Glucagon receptor antagonists, preperation and therapeutic uses
MX2011008450A (es) Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos.
MX336881B (es) Compuestos heterociclicos triciclicos.
PH12012501800A1 (en) 2,3 dihydro- 1h - inden- 1 - yl -2,7 -diazaspirol [ 3.5 ] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor
CL2007003441A1 (es) Compuestos derivados de 1,4-diazepam sustituido, antagonistas del receptor de orexina; composicion farmaceutica; y uso para el tratamiento o prevencion de un trastorno del sueno, para potenciar la calidad del sueno, y para tratar o controlar la obesi
ATE482210T1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
PH12013500958A1 (en) Piperidinone carboxamide azaindane cgrp receptor antagonists
MX2009000900A (es) Derivados de imidazolonas sustituidas, preparacion y usos.
ATE530524T1 (de) Substituierte sulfonamid-derivate
EA201100161A1 (ru) Производные хинуклидина карбоната и их медицинские композиции
EA201390977A1 (ru) Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона
BRPI1014902A2 (pt) composto antagonista de p2x7r, sua composição e seus usos
UA92670C2 (ru) Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе
MX390264B (es) Antagonistas d2, metodos de sintesis y metodos de uso.
NZ601383A (en) Methods and compositions for improved nerve conduction velocity
EA201300436A8 (ru) Совместные кристаллы и соли ингибиторов ccr3
MX2009003645A (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3.
MX2012001160A (es) Agonistas del receptor de esfingosina-1-fosfato.
MA32945B1 (fr) Tétrahydropyrane spiro pyrrolidinone et pipéridinone substituées, leur préparation et leur utilisation thérapeutique
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten
EA200802000A1 (ru) Фармацевтически приемлемые соли и полиморфные формы
MX2009006346A (es) Derivados de 8-etinilxantina como antagonistas de receptores de a2a selectivos.